Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Rasagiline

Nature Reviews Drug Discovery volume 4, pages 625–626 (2005)Cite this article

Abstract

Rasagiline (Azilect; Lundbeck/Teva Pharmaceutical Industries) was given marketing approval by the EMEA for the treatment of Parkinson's disease in February 2005. It is the first in a new generation of selective monoamine oxidase inhibitors, and acts to alleviate the dopaminergic deficit characteristic of the disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Therapies for Parkinson's disease.

References

  1. Lang, A. E. & Lozano, A. M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044–1053 (1998).

    Article  CAS  Google Scholar 

  2. Lang, A. E. & Lozano, A. M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339, 1130–1143 (1998).

    Article  CAS  Google Scholar 

  3. Riederer, P. et al. Clinical applications of MAO-inhibitors. Curr. Med. Chem. 11, 2033–2043 (2004).

    Article  CAS  Google Scholar 

  4. Siddiqui, M. A. & Plosker, G. L. Rasagiline. Drugs Aging 22, 83–91 (2005).

    Article  Google Scholar 

  5. EMEA product information [online], <http://www.emea.eu.int/humandocs/PDFs/EPAR/Azilect/H-574-PI-en.pdf> (2005).

  6. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561–566 (2004).

  7. Analysis of IMS data.

  8. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62, 241–248 (2005).

  9. Rascol, O. et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365, 947–954 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Neurosciences, Royal Free and University College Medical School, London, NW3 2PF, UK

    Anthony Schapira

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Guy Bate

  3. Nature Reviews Drug Discovery, UK

    Peter Kirkpatrick

Authors
  1. Anthony Schapira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guy Bate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schapira, A., Bate, G. & Kirkpatrick, P. Rasagiline. Nat Rev Drug Discov 4, 625–626 (2005). https://doi.org/10.1038/nrd1803

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1803

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing